Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM201 and Midostaurin in Relapsed/Refractory AML
NCT04496999Phase 1Terminated
- Sponsor
- Insel Gruppe
- Start
- Jul 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of siremadlin in acute myeloid leukemia (AML), sponsored by Insel Gruppe. Primary endpoint: Dose finding at 30 days. Started Jul 2020; status: terminated.
02
Drugs
siremadlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04496999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04496999.